Update shared on29 Aug 2025
Fair value Increased 19%The significant upward revision in Hyperfine’s consensus analyst price target is primarily driven by a notable increase in its forecasted Future P/E, with fair value rising from $1.19 to $1.42.
What's in the News
- Hyperfine provided 2025 earnings guidance, expecting 10%–20% revenue growth over 2024.
- Successful enrollment of 100 patients in the NEURO PMR study supports commercial expansion into outpatient neurology offices; a strategic partnership with NeuroNet Pro was announced to drive adoption.
- Next-generation Swoop system, powered by Optive AI software, achieved first commercial sales to two top-tier hospitals after FDA clearance, with a focus on ICUs and emergency departments.
- Optive AI software commercially launched for existing and new Swoop users, enhancing image quality without hardware changes and supporting broad clinical use cases.
- Interim CARE PMR study results showed Swoop achieved 100% sensitivity for detecting ARIA-E in Alzheimer's patients; studies and adoption continue to highlight improved point-of-care imaging for dementia and brain emergencies.
Valuation Changes
Summary of Valuation Changes for Hyperfine
- The Consensus Analyst Price Target has significantly risen from $1.19 to $1.42.
- The Future P/E for Hyperfine has significantly risen from 49.97x to 59.30x.
- The Discount Rate for Hyperfine remained effectively unchanged, moving only marginally from 7.48% to 7.47%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.